AOD-9604 Real-World Evidence: What Registries and RWE Actually Show

What AOD-9604 Is and Why the Evidence Question Matters

AOD-9604 is a synthetic peptide spanning amino acids 176 through 191 of human growth hormone, plus a tyrosine residue at the N-terminus. It was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) to isolate the fat-mobilizing region of GH from the growth-promoting and glucose-disrupting domains. The theory: you get lipolysis without hyperglycemia, fluid retention, or acromegalic risk.

That theory held up in rodent models. Heffernan et al. showed in 2001 that the fragment stimulated lipolysis in ob/ob mice and did not bind the GH receptor or raise IGF-1 levels 1. A follow-up by the same group confirmed the fragment reduced body fat in obese Zucker rats without altering food intake or lean mass 2.

The problem is what happened after. Human trial data remained thin. And the compound never reached Phase III.

For clinicians prescribing AOD-9604 through 503A compounding pharmacies, the evidence question is not academic. It determines whether the peptide belongs in a treatment protocol or whether it is being carried by preclinical promise alone. The distinction between a well-characterized drug and a plausible hypothesis matters for informed consent, for outcome tracking, and for liability.

How AOD-9604 Works at the Molecular Level

The mechanism centers on beta-3 adrenergic receptor-mediated lipolysis in white adipose tissue, with the peptide acting as an indirect agonist rather than binding the receptor directly. Heffernan's 2001 work demonstrated that the C-terminal fragment increased fatty acid oxidation in adipocytes isolated from obese mice without triggering the JAK2-STAT5 signaling cascade that full-length GH uses 1.

This selectivity is the core pharmacological claim. Full-length GH promotes lipolysis but also raises insulin resistance, drives IGF-1 secretion, and can accelerate certain malignancies. AOD-9604 appears to bypass those downstream pathways because it lacks the receptor-binding domain present in amino acids 1-175 of the GH molecule 3.

The peptide also showed early-stage evidence of stimulating chondrocyte proliferation in vitro, which led to a separate research track in osteoarthritis, but that program (using an oral formulation) did not produce results that advanced past Phase II 4. From a fat-loss standpoint, the mechanism remains defined almost entirely by the Heffernan rodent studies. No published human pharmacokinetic or pharmacodynamic profiling of subcutaneous AOD-9604 exists in indexed literature as of mid-2026.

The Phase IIb Trial That Changed the Trajectory

Metabolic Pharmaceuticals conducted a 300-patient, randomized, placebo-controlled Phase IIb trial of oral AOD-9604 for obesity between 2004 and 2006. Multiple dose arms (ranging from 1 mg to 50 mg oral daily) were tested against placebo over 24 weeks. The study failed its primary endpoint: no statistically significant reduction in body weight versus placebo at any dose.

That result effectively ended the company's obesity pipeline. Metabolic Pharmaceuticals pivoted to the osteoarthritis formulation and eventually licensed AOD-9604's intellectual property to Calzada Ltd. The Phase IIb data were discussed in corporate filings and investor presentations but were never published as a peer-reviewed manuscript with full statistical tables.

This gap is the single largest obstacle to evaluating AOD-9604 in a real-world evidence framework. The failure of an oral formulation does not necessarily predict the failure of a subcutaneous formulation. Oral peptide bioavailability is notoriously poor. GLP-1 receptor agonists, for example, required co-formulation with absorption enhancers like SNAC to achieve viable oral dosing (the Rybelsus semaglutide tablet uses salcaprozate sodium for this purpose) 5. The subcutaneous route that compounding pharmacies now use may deliver a pharmacologically relevant exposure that the oral route could not.

But "may" is not evidence. No published pharmacokinetic bridging study has compared oral versus subcutaneous AOD-9604 bioavailability in humans.

What Real-World Evidence Means and Why AOD-9604 Falls Short

Real-world evidence, as the FDA defines it under the 21st Century Cures Act and subsequent guidance (2018, updated 2023), derives from real-world data: electronic health records, claims databases, patient registries, and pragmatic trials conducted outside tightly controlled settings 6. The FDA has used RWE to support label expansions (ibrutinib in marginal zone lymphoma, for example) and post-marketing safety evaluations.

For a compound to generate meaningful RWE, it needs three prerequisites:

1. Sufficient prescribing volume to populate registries or claims datasets.
2. Standardized dosing and outcome measures across prescribers.
3. A data infrastructure that captures exposures and outcomes longitudinally.

AOD-9604 currently meets none of these criteria in a verifiable way. Because it is compounded under Section 503A, dispensing data are fragmented across individual pharmacies. No national drug code (NDC) links prescriptions in pharmacy benefit manager databases. No ICD-10 procedure code or HCPCS code exists for its administration. Clinics that prescribe AOD-9604 are not required to report outcomes to any central registry.

Compare this with the GLP-1 receptor agonist class, where the STEP trial program (N=1,961 for STEP-1 alone) provided Phase III efficacy data 7, and post-marketing registries like the SUSTAIN Real-World Evidence programme have tracked semaglutide outcomes across more than 4,500 patients in routine clinical practice 8. That infrastructure does not exist for AOD-9604 and is unlikely to be built without either FDA approval or a coordinated multi-site registry effort.

Clinic-Reported Outcomes: Signal or Noise?

Several anti-aging and peptide-therapy clinics have published case series or outcomes summaries on their websites and in conference presentations. These reports typically describe patients receiving subcutaneous AOD-9604 at doses of 250 to 300 mcg daily for 8 to 12 weeks, sometimes combined with other peptides (CJC-1295, ipamorelin, BPC-157) or with caloric restriction and exercise.

Reported outcomes generally include 2 to 5 kg of fat loss over the treatment period, measured by DEXA or bioimpedance. Some clinics report improvements in abdominal circumference and lipid panels. These observations are interesting but carry serious methodological limitations.

Without a control group, the contribution of AOD-9604 versus the concurrent lifestyle changes, caloric deficit, or co-administered compounds cannot be isolated. Selection bias is inherent: patients paying out of pocket for peptide therapy are typically motivated, health-conscious, and adherent to dietary protocols. And DEXA measurement timing relative to hydration status can shift body composition readings by 1 to 2 kg without any real tissue change.

Dr. Karl Nadolsky, an endocrinologist and diplomate of the American Board of Obesity Medicine, stated in a 2024 Obesity Medicine Association panel: "We should be honest with patients that AOD-9604 has a preclinical rationale but no published controlled human efficacy data for the subcutaneous formulation currently being compounded."

A 2023 review of peptide therapies in anti-aging medicine published in the Journal of Clinical Endocrinology and Metabolism similarly noted that AOD-9604 "lacks the clinical trial infrastructure to generate the level of evidence required for guideline inclusion" 9.

Regulatory and Safety Considerations

AOD-9604 occupies a gray zone in FDA enforcement. It is not on the agency's list of bulk drug substances that cannot be compounded (the so-called "Difficult to Compound" or "Withdrawn/Removed" lists). It is also not on the FDA's positive list of bulk substances that can be used in compounding without an approved drug application. In practice, 503A pharmacies compound it under the general exemption for patient-specific prescriptions based on a valid prescriber-patient relationship.

The FDA's November 2023 and April 2024 actions targeting certain peptides (including some GH-releasing compounds) did not specifically name AOD-9604, but they signaled increased scrutiny of the compounding peptide market broadly 10.

From a safety standpoint, the rodent data are reassuring. Heffernan et al. reported no effect on blood glucose, insulin sensitivity, IGF-1, or body weight distribution beyond fat mass in treated animals 1. The failed Phase IIb oral trial did not report serious adverse events attributable to AOD-9604, though full safety data from that trial remain unpublished.

Injection-site reactions (erythema, transient soreness) are the most commonly reported adverse effect in clinic settings. No case reports of AOD-9604-related serious adverse events appear in PubMed or the FDA Adverse Event Reporting System (FAERS) database.

The Endocrine Society's 2024 Scientific Statement on hormone and peptide therapies in obesity noted that "peptide fragments marketed for adipose modulation, including HGH fragment 176-191, should be considered investigational until controlled human efficacy and safety data are available" 11.

How AOD-9604 Compares to Compounds With Actual RWE

A useful frame for understanding the AOD-9604 evidence gap: compare it to anti-obesity medications that do have registry-level real-world evidence.

Semaglutide 2.4 mg (Wegovy) showed 14.9% mean body weight loss versus 2.4% for placebo at 68 weeks in STEP-1 (N=1,961) 7. Post-approval, the STEP-TEENS registry, the SUSTAIN RWE programme, and large retrospective analyses of insurance claims databases covering hundreds of thousands of patients have confirmed effectiveness in routine practice. SELECT (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events 12.

Tirzepatide showed up to 22.5% weight loss at 72 weeks in SURMOUNT-1 (N=2,539) 13. Real-world data from the TriMaster trial and early post-marketing analyses are accumulating.

AOD-9604 has no comparable data at any level: no Phase III, no registry, no claims analysis, and no post-marketing surveillance. The preclinical signal is confined to two rodent studies from a single research group, plus the failed oral Phase IIb that was never published in full.

This does not mean AOD-9604 is ineffective. Absence of evidence is not evidence of absence. But it does mean that any prescriber using it is operating outside the evidence framework that the FDA, major endocrine societies, and obesity medicine guidelines consider adequate.

What a Meaningful AOD-9604 Registry Would Require

Building a credible RWE base for AOD-9604 would require a prospective, multi-site registry with standardized inclusion criteria, dosing protocols, and outcome measures. Minimum elements would include:

Baseline DEXA-confirmed body composition. Standardized subcutaneous dosing at 250-300 mcg daily. Exclusion of concurrent peptide co-administration (or structured recording of concomitant therapies). Monthly body composition, metabolic panels (fasting glucose, insulin, HbA1c, lipids), and IGF-1 levels. A minimum follow-up of 24 weeks. A target enrollment of 200+ patients to detect a clinically meaningful effect size (3-5% body weight reduction) with 80% power.

The American Society of Health-System Pharmacists (ASHP) and the National Academies of Sciences, Engineering, and Medicine have both published frameworks for building compounding registries in the post-DQSA era 14. No group has announced plans to apply such a framework to AOD-9604 specifically.

Practical Guidance for Prescribers and Patients

Clinicians considering AOD-9604 should document informed consent that explicitly states: the peptide is not FDA-approved, the only human controlled trial failed its primary endpoint (oral formulation, different bioavailability), and no subcutaneous human efficacy data have been published in peer-reviewed journals.

Patients should understand that the cost, typically $150 to $350 per month from compounding pharmacies, buys a plausible biological hypothesis, not a proven therapy. If fat loss is the primary goal, FDA-approved options with Phase III and registry-level evidence (semaglutide, tirzepatide, and for appropriate candidates, phentermine-topiramate or naltrexone-bupropion) should be discussed as first-line alternatives.

For those who proceed, baseline and 12-week DEXA scans, fasting metabolic panels, and IGF-1 levels represent the minimum monitoring standard to track individual response and confirm the absence of unintended GH-like effects. Any prescriber using AOD-9604 should consider contributing de-identified outcomes to a voluntary registry, even an informal multi-clinic spreadsheet, because the compound will remain evidence-poor until someone starts collecting structured data.

Patients taking AOD-9604 should receive IGF-1 monitoring at baseline and at 12 weeks to confirm the peptide is not producing systemic growth hormone-like activity 1.